A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs

Inclusion Criteria: * Be male or female * Be aged 18-59. * Has a BMI between 20-31.9. * Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®) * Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours. * Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial. * Anyone willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of this trial. * Anyone who is generally healthy - does not live with any diagnosed uncontrolled chronic disease. * Has access to a consistent weighing scale for the duration of the study. * Resides in the United States. Exclusion Criteria: * Anyone with a diagnosis of Type I or Type II diabetes. * Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia. * Anyone who has taken any multivitamin/multimineral supplements within the past 3 months. * Anyone who has taken a probiotic supplement within the past month. * Anyone who has regularly consumed (5 days/week or more) products that target healthy aging, anti-aging,…